HCPCS Code J9035: Bevacizumab Billing and Medicare Guide

Key Takeaways

HCPCS Code J9035 describes bevacizumab (Avastin), billed per 10 mg administered – divide the total dose in mg by 10 to get your unit count.

Medicare reimburses J9035 at ASP plus 6% in physician office settings; rates update quarterly and must be verified against current CMS ASP pricing files.

Billing the wrong number of units is the most common audit trigger for J9035 – always document the exact milligrams administered, not the vial size.

Practice management software like Pabau centralizes the dose, diagnosis, and prior-authorization documentation that supports accurate J9035 billing.

HCPCS Code J9035 is the billing code for bevacizumab, the VEGF-inhibiting monoclonal antibody marketed as Avastin. It has been in active use since bevacizumab’s first FDA approval in 2004, and it’s billed per 10 mg administered, not per vial. Billing rules have grown more complex as biosimilar alternatives entered the market with their own code assignments.

In short, this reference covers the official descriptor, unit calculation, Medicare reimbursement methodology, covered ICD-10 diagnosis codes, biosimilar code distinctions, place of service rules, and documentation requirements for a clean J9035 claim. Rates change quarterly – always verify current figures against the CMS ASP Drug Pricing Files before submitting.

HCPCS Code J9035: definition and code details

HCPCS Code J9035 is the Level II code assigned by CMS to bevacizumab, the VEGF-inhibiting monoclonal antibody marketed as Avastin by Genentech/Roche. The official descriptor reads: Injection, bevacizumab, 10 mg. In addition, this is a chemotherapy J-code in the antineoplastic drug category, billed per 10 mg of drug administered by intravenous infusion.

Other antineoplastic drugs follow the same per-10-mg billing convention, such as J9025, though each carries its own dosage and diagnosis requirements.

According to the CMS HCPCS Level II overview, J-codes in the antineoplastic category apply to drugs administered by a healthcare professional in a clinical setting. J9035 covers both the reference product (Avastin) and, in certain CMS determinations, biosimilar bevacizumab products – though biosimilars increasingly carry their own Q-codes. See the biosimilars section below for current code assignments.

J9035 units billing: how to calculate and avoid errors

The per-10-mg billing unit is where most J9035 claim errors originate. Bevacizumab vials come in 100 mg/4 mL and 400 mg/16 mL concentrations. Billing staff who enter the vial count rather than calculating actual milligrams administered will consistently overbill, which is an audit red flag. Instead, the correct formula is simple: units billed = total mg administered divided by 10.

Round to the nearest whole unit when the administered dose produces a fraction. CMS billing policy for Part B drugs does not allow billing for partial units. Ultimately, always base the unit count on the dose actually administered, documented in the infusion record, not the amount prepared or ordered.

In addition, practices managing high-volume bevacizumab infusion schedules can benefit from reviewing infusion therapy documentation practices to keep administered-dose records audit-ready. When bevacizumab is delivered through a central venous catheter, bill the catheter supply separately under C1722 rather than folding it into the drug charge.

Bevacizumab Medicare coverage: indications for J9035

Medicare Part B covers J9035 for FDA-approved oncology indications and for off-label uses recognized by CMS-approved compendia. In addition, coverage is governed by CMS billing article A52370 and applicable Local Coverage Determinations (LCDs) from your Medicare Administrative Contractor (MAC).

Off-label coverage requires documentation that the indication is listed in a CMS-recognized compendium such as the NCCN Guidelines or the AMA Drug Evaluations. Understanding who can administer IV infusions is also relevant to coverage determination, as place of administration affects which benefit category applies.

FDA-approved indications for bevacizumab (Avastin) include:

• Metastatic colorectal cancer (mCRC), first- and second-line
• Non-squamous non-small cell lung cancer (NSCLC), first-line
• Glioblastoma (GBM), recurrent
• Metastatic renal cell carcinoma (mRCC)
• Persistent, recurrent, or metastatic cervical cancer
• Platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Hepatocellular carcinoma (HCC), unresectable
• Endometrial carcinoma (certain combinations)

Colorectal cancer, the most common bevacizumab indication, is typically confirmed through a diagnostic colonoscopy such as 45378 before staging establishes metastatic disease and bevacizumab therapy begins.

For example, off-label coverage for wet age-related macular degeneration (AMD) via intravitreal injection may be available under certain MAC jurisdictions and compendium support. Verify with your specific MAC before billing off-label indications, as prior authorization requirements and coverage criteria vary by jurisdiction.

J9035 ICD-10 diagnosis codes: covered diagnoses

Every J9035 claim requires an ICD-10-CM diagnosis code that supports medical necessity, as required by CMS billing article A52370. In other words, the diagnosis code must reflect the condition being treated, not the drug administered. The table below lists the primary ICD-10-CM codes that support coverage for bevacizumab infusion across major cancer types.

This table reflects commonly accepted ICD-10-CM codes. However, always verify against your MAC’s current LCD and the CMS Medicare Coverage Database before submitting claims. The most specific code available must be used – unspecified codes invite additional scrutiny.

Similarly, practices billing for the gynecologic indications – cervical, ovarian, or endometrial cancer – often pair diagnosis coding accuracy with OB-GYN practice management software to keep documentation aligned with treatment records.

J9035 Medicare reimbursement rate and fee schedule

Medicare reimburses J9035 using the Average Sales Price (ASP) methodology. In particular, the standard payment for physician office settings is ASP plus 6%. By contrast, hospital outpatient department (HOPD) reimbursement follows the Outpatient Prospective Payment System (OPPS) and is typically lower on a per-unit basis. The 6% add-on covers storage, handling, and administration overhead in the physician office setting.

ASP rates update every quarter, and the dollar figure per 10 mg changes with each quarterly CMS release – always confirm the current rate before submitting claims. In contrast, commercial payer rates for J9035 vary significantly by payer and contract and are not governed by the ASP methodology.

Place of service and bill type codes for J9035

The place of service (POS) code on a J9035 claim directly affects payment rate. For example, mismatched POS codes – billing POS 11 for a service performed at a hospital outpatient facility – are a common reason for post-payment adjustments.

Therefore, practices operating across multiple settings (office, infusion suite, hospital) should verify which POS applies to each administration. Those running a mobile infusion service should review considerations for running a mobile IV therapy business to understand setting-specific billing implications.

Hospital outpatient claims use the UB-04 form with bill type 13X. Conversely, physician office claims use the CMS-1500. The claim form type must match the billing entity and the setting where the service was actually performed.

Biosimilar bevacizumab HCPCS codes

In addition, several FDA-approved bevacizumab biosimilars are available in the US market. Each one carries its own dedicated HCPCS Q-code rather than sharing J9035, so billing the reference product code for a biosimilar will trigger a denial. Confirm the correct code for each biosimilar before every claim cycle.

Notably, for bevacizumab specifically, none of the FDA-approved biosimilars share J9035 – each has carried its own Q-code since the effective date CMS assigned at launch. The AAPC HCPCS code lookup confirms current code assignments, and the quarterly CMS ASP drug pricing file lists the payment rate for each Q-code.

J9035 documentation requirements

Documentation for a J9035 claim must support medical necessity, confirm the dose administered, and link the treatment to a covered diagnosis. In fact, incomplete documentation is the primary driver of post-payment audits for high-cost oncology drugs.

Practices benefit from using digital clinical documentation forms to capture infusion data at the point of care rather than reconstructing it after the fact, and maintaining HIPAA-compliant record-keeping requirements throughout the care episode.

Required documentation for a clean J9035 claim includes:

• Diagnosis confirmation: Pathology report or imaging confirming the malignancy and stage corresponding to the billed ICD-10-CM code
• Physician order: A signed, dated order specifying the drug, dose in milligrams, route (IV), and frequency
• Dose administered: Infusion record showing the exact milligrams delivered, start and stop time, and the nurse or provider who administered the infusion
• Medical necessity documentation: Treatment plan or progress note linking the bevacizumab regimen to the covered indication
• Compendia reference (off-label only): Citation of the CMS-recognized compendium supporting the off-label indication, with the specific entry referenced
• Prior authorization record (if required): Approval number, effective date, and payer name when your MAC or commercial payer requires pre-authorization for J9035
• Waste or no-waste documentation: Record any amount discarded with modifier JW, or attest zero waste with modifier JZ – JZ reporting is mandatory on every applicable claim, even when the full vial was administered

Good medical practice compliance workflows build documentation capture into the clinical workflow rather than treating it as a billing afterthought. In particular, auditors reviewing J9035 claims look first at whether the dose in the infusion record matches the units billed on the claim.

Billing instructions and common errors for J9035

In general, clean J9035 claims follow a predictable sequence. Errors cluster around three failure points: wrong units, wrong POS, and missing or mismatched diagnosis codes. Staff with experience launching an IV infusion practice know that billing accuracy for high-cost drugs requires both system support and staff training.

1. Verify the administered dose: First, confirm the exact milligrams given with the administering nurse before the claim is built.
2. Calculate units: Divide total mg by 10. Then round to the nearest whole unit. Never use the vial size.
3. Select the correct HCPCS code: J9035 for reference bevacizumab (Avastin). Otherwise, use the appropriate Q-code or J9035 variant for biosimilar products per current CMS guidance.
4. Assign the ICD-10-CM code: Use the most specific code that matches the confirmed, documented diagnosis. By contrast, unspecified codes require additional justification.
5. Set the correct POS: Match POS 11, 19, or 22 to the actual site of administration. Otherwise, a POS mismatch triggers payment adjustments.
6. Check prior authorization status: Also confirm authorization is active, within its date range, and covers the specific dose planned.
7. Submit with complete documentation: Finally, attach the infusion record and any required compendia references for off-label billing.

The most common errors that trigger J9035 denials or audits are:

Simplify oncology infusion documentation with Pabau

Pabau helps infusion practices capture administered doses and diagnosis details at the point of care, so billing staff have everything they need to build accurate HCPCS claims. See how Pabau keeps J9035 documentation audit-ready.

Book a demo

How practice management software supports J9035 billing

Billing J9035 accurately at volume requires more than staff training. Instead, high-cost drug claims need a system that captures the administered dose in the clinical record and carries it through to the claim without manual re-entry.

Re-keying milligram figures from paper infusion sheets into a billing platform is a consistent source of unit errors. Oncology and infusion practices using IV therapy practice management platforms designed for drug administration workflows reduce this risk by connecting the clinical record to the claim at the source.

Pabau centralizes the documentation that supports accurate J9035 billing: the milligrams administered, the diagnosis code tied to the treatment plan, and any prior-authorization records. Staff can pull the infusion record straight from the patient’s chart instead of reconstructing it after the fact, which cuts the documentation gaps that lead to post-payment audits.

Practices managing EMR software for IV therapy clinics at scale see the biggest benefit when clinical documentation and billing prep run through the same platform rather than separate systems.

Conclusion

Ultimately, J9035 claims are high-value and closely reviewed. The unit calculation error (vials billed instead of milligrams administered) remains the single most common audit trigger, and it is entirely preventable with a clinical workflow that captures the administered dose before the claim is built.

Pabau keeps drug administration documentation connected to the diagnosis and dosing details billing staff need, so the units on the claim reflect what the infusion record shows. For oncology and infusion practices ready to tighten their J9035 billing accuracy, that starts with a documentation workflow built around the point of care.

Continue your research

Need guidance on IV infusion clinic compliance requirements? IV therapy clinic best practices covers documentation, safety protocols, and operational standards for infusion settings.

Evaluating practice management platforms for your infusion service? Best EMR software for IV therapy compares the leading platforms for drug administration and billing workflows.

Ready to open an IV infusion clinic? How to open an IV therapy clinic walks through licensing, equipment, staffing, and billing setup from start to finish.

Frequently asked questions